Probiotics for Crohn's Disease: Strains & Clinical Evidence

person Nicholas Wunder
calendar_today Apr 20, 2026
comment 0 comments

Calm man in his late 30s sitting on a couch in soft morning light holding a warm ceramic mug, with one hand resting on his lower abdomen, representing the experience of someone managing Crohn's disease with intentional gut health support.

Probiotics for Crohn's Disease: Evidence-Based Strains, Mechanisms & What Research Shows

A research-backed guide to probiotic strains studied in Crohn's disease — and what the clinical evidence actually says

Crohn's disease is a chronic inflammatory bowel disease that disrupts not just the digestive tract, but every system the gut influences — energy, immunity, mood, and quality of life. Conventional treatment focuses on calming the immune system with anti-inflammatory drugs, immunomodulators, and biologics. But over the past two decades, researchers have turned increasing attention to a different lever: the trillions of bacteria living in the gut itself.

People with Crohn's disease consistently show a disrupted gut microbiome — reduced diversity, lower populations of anti-inflammatory bacteria, and an overgrowth of pro-inflammatory species. This pattern, known as dysbiosis, isn't just a side effect of inflammation. Mounting evidence suggests it actively contributes to it. That's the premise behind probiotic research in Crohn's: if dysbiosis fuels inflammation, can introducing beneficial bacteria help dampen it?

The honest answer is that the evidence is mixed and still developing. Probiotics aren't a replacement for medical therapy in Crohn's disease, and the strongest clinical results have come from specific strains studied in specific contexts — not from generic probiotic use. This guide walks through what the peer-reviewed research actually shows about probiotic strains in Crohn's disease, the mechanisms by which they appear to work, and how to think about them as a complement (not a substitute) to standard care.

Key Takeaways

Crohn's disease is associated with significant gut dysbiosis, particularly a reduction in the anti-inflammatory bacterium Faecalibacterium prausnitzii and overall microbial diversity.^[1]
A 2025 meta-analysis of 16 randomized controlled trials involving 1,112 patients found that probiotics significantly increased the likelihood of clinical remission in patients with active Crohn's disease (RR 1.27, 95% CI 1.09–1.47).^[2]
Lactobacillus casei directly downregulates pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-8) in inflamed Crohn's disease mucosa and counteracts the inflammatory effects of pathogenic bacteria, according to ex vivo research from Vall d'Hebron University Hospital.^[3]
A synbiotic combining Bifidobacterium longum with prebiotic fiber significantly reduced Crohn's Disease Activity Index scores, histological damage, and TNF-α expression in a placebo-controlled trial of patients with active CD.^[4]
Multi-strain probiotic formulations show more consistent benefit than single strains in CD research, likely because they address dysbiosis through multiple complementary mechanisms.^[5]
Probiotics are generally considered safe in Crohn's disease, with no significant increase in serious adverse events compared to placebo across pooled clinical trials.^[2]
Probiotics are not a replacement for medical therapy in Crohn's disease. They should be considered as a potential adjunct to — not a substitute for — treatment prescribed by a gastroenterologist.

Understanding Crohn's Disease and the Microbiome

Crohn's disease (CD) is a form of inflammatory bowel disease (IBD) characterized by chronic, transmural inflammation that can affect any part of the gastrointestinal tract from the mouth to the anus. Most commonly, the inflammation appears in the terminal ileum and adjacent colon. Symptoms include abdominal pain, persistent diarrhea, weight loss, fatigue, and — over time — complications such as strictures, fistulas, and the need for surgical resection.

Unlike ulcerative colitis, which is confined to the colon's mucosal layer, Crohn's disease can extend through the entire intestinal wall and skip between affected and unaffected segments. This "patchy" pattern and the depth of inflammation make CD distinct — and harder to treat with any single intervention, including probiotics.

The Dysbiosis Signature of Crohn's Disease

One of the most consistent findings in Crohn's disease research is that patients show a markedly altered gut microbiome compared to healthy individuals. Studies have documented a reduced diversity of intestinal bacteria, with particularly notable depletion of anti-inflammatory species within the Firmicutes phylum.^[6] Among these, Faecalibacterium prausnitzii — a major butyrate producer with well-established anti-inflammatory properties — is consistently reduced in CD patients. Lower levels of F. prausnitzii on resected ileal mucosa have even been associated with higher rates of endoscopic recurrence after surgery.^[1]

At the same time, CD patients tend to show an expansion of pro-inflammatory bacteria, including adherent-invasive Escherichia coli (AIEC) strains that can adhere to and invade the intestinal mucosa. The result is a microbial environment tilted away from balance — fewer anti-inflammatory signals, more inflammatory ones, and a weakened intestinal barrier. For a deeper look at this imbalance pattern, see our guide on gut dysbiosis and probiotics.

Scientific infographic comparing a healthy gut microbiome with abundant beneficial bacteria including Bifidobacterium and Faecalibacterium prausnitzii against the dysbiotic Crohn's disease microbiome showing reduced bacterial diversity and weakened intestinal barrier.

Why Microbiome Changes Matter in Crohn's

The dysbiosis seen in Crohn's disease isn't just a passive marker — research suggests it actively participates in the inflammatory cascade. Diversion of the fecal stream away from inflamed bowel segments has been shown to induce remission in Crohn's, while reintroducing intestinal contents reactivates mucosal lesions.^[7] This points to gut bacteria as more than bystanders in CD — they appear to be participants. That's the rationale for studying probiotics as a way to modulate the microbial environment toward a less inflammatory state.

How Probiotics May Help in Crohn's Disease

The hypothesis behind probiotic research in Crohn's disease is straightforward: if dysbiosis contributes to mucosal inflammation, then introducing beneficial bacteria might help restore balance and reduce inflammatory signaling. The mechanisms by which probiotics could exert this effect have been studied extensively in cell cultures, animal models, and — to a lesser extent — clinical trials.

Modulating the Inflammatory Response

Several Lactobacillus and Bifidobacterium strains have been shown to directly reduce the production of pro-inflammatory cytokines that drive intestinal inflammation in CD. Researchers at Vall d'Hebron University Hospital demonstrated that live Lactobacillus casei, when incubated with mucosal explants from Crohn's disease patients, significantly decreased the secretion of TNF-α, IFN-γ, IL-2, IL-6, IL-8, and CXCL1 — all key inflammatory mediators in the disease.^[3] A separate study from the same research group showed that L. casei can prevent and counteract the pro-inflammatory effects of E. coli on Crohn's disease mucosa, suggesting a potential role in dampening flare-driving bacterial signals.^[8]

Bifidobacterium longum has shown similar anti-inflammatory potential. It can attenuate LPS-induced activation of NF-κB — a master regulator of inflammation — and reduce TNF-α and IL-8 production in intestinal epithelial cells.^[9] B. longum subsp. infantis additionally produces indole-3-lactic acid, an anti-inflammatory metabolite that activates protective pathways in gut cells.^[9]

Strengthening the Intestinal Barrier

One of the underlying problems in Crohn's disease is increased intestinal permeability — the so-called "leaky gut" phenomenon, where the tight junctions between intestinal cells become compromised, allowing bacterial products to reach the underlying immune tissue and trigger inflammation. Multiple Bifidobacterium and Lactobacillus species have been shown to upregulate tight junction proteins (zonula occludens-1, occludin, claudin-1) and reinforce mucus layer integrity.^[10]

Lactobacillus plantarum, in particular, has demonstrated robust effects on barrier function in animal colitis models — increasing tight junction protein expression, decreasing intestinal permeability, and reducing pro-inflammatory cytokine levels.^[11] The clinical relevance of this barrier support is explored further in our article on probiotics for leaky gut barrier repair.

Competing With Pathogenic Bacteria

Probiotic strains can occupy mucosal binding sites that would otherwise be available to pathogenic bacteria, produce antimicrobial compounds, and lower local pH through lactic acid production. Research has shown that Lactobacillus and Bifidobacterium strains can significantly reduce the adhesion and persistence of adherent-invasive E. coli within intestinal epithelial cells — a mechanism with direct relevance to Crohn's disease, where AIEC strains are implicated in driving inflammation.^[12]

Supporting Short-Chain Fatty Acid Production

Short-chain fatty acids (SCFAs) — particularly butyrate — are the primary energy source for colonocytes and play a central role in maintaining gut health. The depletion of butyrate-producing species like F. prausnitzii in Crohn's disease is thought to contribute to the inflammatory environment. While direct supplementation with these obligate anaerobes is technically challenging, certain probiotic and prebiotic combinations can support an environment that favors SCFA production. Our deep dive on how to increase butyrate naturally covers this topic in depth.

Four-quadrant infographic showing the mechanisms by which probiotics may support gut health in Crohn's disease: modulating inflammation by reducing TNF-α and IL-6, strengthening the intestinal barrier through tight junction support, competing with pathogenic bacteria, and supporting short-chain fatty acid production.

Probiotic Strains Studied in Crohn's Disease

Probiotic effects are strain-specific. A study showing benefit for one Lactobacillus strain doesn't mean another Lactobacillus strain will perform the same way. Below are the probiotic species with the most relevant research in Crohn's disease and IBD more broadly — all of which are included in MicroBiome Restore.

Lactobacillus casei

L. casei is one of the more extensively studied probiotic species in the context of Crohn's disease specifically, with mechanistic research demonstrating direct anti-inflammatory effects on inflamed CD mucosa. In a landmark study published in Inflammatory Bowel Diseases, live L. casei significantly downregulated expression of IL-8, IL-6, and CXCL1 in mucosal samples from CD patients, and demonstrated the ability to counteract the pro-inflammatory effects of pathogenic E. coli.^[3]

Animal research has reinforced these findings: L. casei-treated mice with chemically induced colitis showed significantly reduced T cell infiltration and ameliorated cecal inflammation compared to controls, with the strain influencing inflammatory signaling pathways at multiple levels.^[13]

Bifidobacterium longum (including subsp. infantis)

Bifidobacterium longum has emerged as one of the most clinically promising probiotics in Crohn's research, particularly when combined with prebiotic fiber. In the Steed et al. randomized, double-blind, placebo-controlled trial, 35 patients with active CD received either a synbiotic combining B. longum and prebiotic Synergy 1 or placebo for 6 months. The synbiotic group showed significant reductions in Crohn's Disease Activity Index (CDAI) scores, histological damage, and mucosal TNF-α expression at 3 months — improvements that were maintained through the rest of the study.^[4]

Beyond clinical evidence, mechanistic studies show that B. longum can attenuate NF-κB activation, reduce TNF-α and IL-8 in intestinal epithelial cells, and increase production of the anti-inflammatory metabolite indole-3-lactic acid.^[9] B. longum subsp. infantis has demonstrated additional intestinal barrier benefits in colitis models, improving tight junction integrity and reducing intestinal permeability.^[14] For a broader look at this species, see our coverage of Bifidobacterium longum benefits.

Bifidobacterium breve

B. breve is included in well-known multi-strain formulations studied in IBD. As a component of the eight-strain VSL#3 cocktail (which contains B. breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus, and S. thermophilus), B. breve contributes to a formulation with proven efficacy in ulcerative colitis and chronic pouchitis, and has shown signals of benefit in Crohn's disease postoperative recurrence.^[5] Combined with L. casei and prebiotic galacto-oligosaccharides, B. breve-containing synbiotics have also been studied in pediatric patients with refractory enterocolitis, where they were associated with improvements in intestinal function and short-chain fatty acid production.^[15]

Bifidobacterium bifidum, lactis, and infantis

The broader Bifidobacterium genus plays a foundational role in maintaining the intestinal tight junction barrier — a critical factor in preventing the bacterial translocation that drives inflammation in CD. A comprehensive review in Advances in Nutrition highlighted how B. bifidum, B. lactis, B. longum, and B. infantis regulate tight junction proteins and signaling pathways responsible for intestinal barrier integrity.^[10] Murine colitis studies have shown B. lactis protects against colon shortening, reduces apoptosis in intestinal epithelial cells, and decreases TNF-α levels.^[16] Read more about Bifidobacterium lactis benefits for gut health.

Lactobacillus plantarum

L. plantarum has a strong track record in animal models of IBD, where it has demonstrated improved intestinal barrier function, modulated Th1/Th2 immune balance, and prevented or reduced colitis severity. In IL-10 knockout mice (a genetic model of spontaneous colitis), L. plantarum 299v prevented disease onset and reduced established colitis severity.^[11] While clinical trial data in humans with CD specifically remain limited, the mechanistic and preclinical evidence has been consistently encouraging, and L. plantarum is a component of multi-strain formulations studied in IBD. For more, see our coverage of Lactobacillus plantarum health benefits.

Lactobacillus rhamnosus

L. rhamnosus has been extensively studied in IBD, with somewhat mixed results in Crohn's disease specifically. An open-label pediatric pilot showed promising clinical improvement and reduced intestinal permeability with L. rhamnosus GG in children with mild-to-moderate active CD.^[17] However, larger randomized trials of L. rhamnosus GG as monotherapy for relapse prevention in pediatric CD did not show significant benefit over placebo.^[18] The strain remains valuable in multi-strain formulations and for its broader gut health and barrier-supporting properties — see our overview of Lactobacillus rhamnosus benefits for context.

Lactobacillus acidophilus

L. acidophilus is one of the most widely included probiotic species in IBD-focused multi-strain formulations. Research has examined its role in supporting epithelial barrier function alongside B. infantis, with secretions from these two species shown to protect intestinal epithelial barrier integrity in cell models.^[19] Its inclusion in the VSL#3 formulation, which has shown signals of benefit in postoperative Crohn's disease recurrence, supports its role as part of a broader probiotic strategy. Learn more in our guide to Lactobacillus acidophilus benefits.

Lactobacillus paracasei and delbrueckii subsp. bulgaricus

Both species are part of the multi-strain VSL#3 formulation. L. delbrueckii subsp. bulgaricus has demonstrated anti-inflammatory effects on Crohn's disease mucosa in ex vivo studies, reducing TNF-α release alongside L. casei.^[20] L. paracasei has shown ameliorating effects in animal models of Crohn's-like ileitis.^[21]

Streptococcus thermophilus

A staple in fermented dairy products and a component of multi-strain IBD formulations, S. thermophilus has been identified — alongside Lactobacillus and Bifidobacterium species — as a probiotic that can be used to safely promote intestinal health in clinical research.^[22]

Bacillus species (Spore-Forming Probiotics)

Bacillus clausii UBBC-07, in a randomized double-blind controlled trial in both UC and CD patients, was associated with increased abundance of beneficial Firmicutes, Lactobacillus, Bifidobacterium, and Faecalibacterium in the gut microbiota — a particularly relevant finding given the dysbiosis pattern in CD.^[23] Bacillus coagulans spores combined with prebiotic fiber have shown improvements in chronic colonic inflammation in mouse models of IBD-like disease.^[24]

Strain	Primary Mechanism in Crohn's Research	Evidence Type
L. casei	Downregulates TNF-α, IL-6, IL-8 in CD mucosa	Ex vivo studies on CD patient tissue^[3]
B. longum (with prebiotic)	Reduces CDAI, histological score, TNF-α expression	Randomized controlled trial in active CD^[4]
B. infantis	Improves tight junction integrity; produces indole-3-lactic acid	Animal colitis models, mechanistic studies^[14]
B. breve	Component of multi-strain formulas with IBD efficacy	Synbiotic trials, multi-strain RCTs^[15]
L. plantarum	Reinforces tight junctions; modulates immune response	Animal colitis models, mechanistic studies^[11]
L. rhamnosus	Improves intestinal permeability and barrier function	Pediatric pilot studies (mixed results in monotherapy)^[17]
L. acidophilus	Supports epithelial barrier; multi-strain formulation component	Cell culture, multi-strain RCTs^[19]
B. clausii	Increases beneficial gut bacteria abundance in IBD patients	Randomized double-blind RCT^[23]

26 Clinically Studied Strains. Zero Synthetic Fillers.

MicroBiome Restore brings together every strain referenced above — L. casei, B. longum, B. breve, B. infantis, L. plantarum, L. acidophilus, L. rhamnosus, B. clausii, and 18 more — at 15 billion CFU per serving, paired with 9 organic prebiotics in a clean pullulan capsule.

Explore MicroBiome Restore →

What the Clinical Evidence Actually Shows

The honest picture of probiotic research in Crohn's disease is one of cautious optimism mixed with significant uncertainty. The best-quality systematic reviews and meta-analyses don't all agree, and the differences come down to which subpopulations of CD patients are studied, which strains are tested, and what outcomes are measured.

For Active Crohn's Disease (Inducing Remission)

A 2025 systematic review and meta-analysis of 16 randomized controlled trials involving 1,112 patients found that probiotics significantly increased the likelihood of clinical remission in patients with active Crohn's disease, with a relative risk of 1.27 (95% CI 1.09–1.47, p = 0.002).^[2] The authors concluded that probiotics may help enhance clinical remission in active CD, possibly through gut microbiota modulation.

Earlier work by Fujimori et al. studied a high-dose synbiotic combination (75 billion CFU of mixed Bifidobacterium and Lactobacillus strains plus prebiotic psyllium) in 10 active CD patients whose initial therapy with aminosalicylates and prednisolone had failed. After a mean treatment duration of 13 months, 7 of 10 patients showed clinical improvement, with significant decreases in CDAI and IOIBD scores. Two patients were able to discontinue prednisolone entirely, and four others reduced their steroid dose.^[25]

For Maintaining Remission

Results for maintaining remission in CD have been less consistent. A 2025 systematic review of 11 trials examining probiotics for maintenance of remission in adult-onset CD found inconclusive results, with four trials showing a non-statistically significant trend favoring probiotic administration for relapse prevention.^[26] The 2025 meta-analysis similarly found no significant effect on clinical relapse in patients already in remission, nor a significant reduction in endoscopic recurrence after ileocecal resection.^[2]

The Cochrane Review on probiotics for induction of remission in CD, which included only two studies meeting strict inclusion criteria, concluded that the evidence is of very low certainty due to small sample sizes and methodological heterogeneity, and that no firm conclusions can be drawn — while explicitly noting that no serious adverse events occurred in either study.^[27]

The Synbiotic Signal

One of the more consistent positive signals in CD probiotic research has come from synbiotic combinations — probiotics paired with prebiotic fibers. The Steed et al. trial of B. longum plus Synergy 1 in active CD remains one of the most rigorously designed positive trials in the field, with significant improvements in CDAI, histology, and TNF-α expression.^[4] The mechanism makes biological sense: probiotic strains can only thrive in environments where they have appropriate substrate, and prebiotic fibers provide exactly that.

Clinical trial data visualization comparing baseline versus 6-month results in active Crohn's disease patients receiving Bifidobacterium longum plus prebiotic synbiotic therapy, showing reductions in CDAI score, histological damage, and TNF-α inflammatory marker expression.

Honest Assessment: Where the Evidence Stands

Stronger evidence: Probiotics may help induce remission in patients with active CD, particularly when used as a synbiotic combination with prebiotic fiber. Multi-strain formulations appear more effective than single strains. Probiotics are safe in CD patients, with no significant increase in serious adverse events.

Weaker evidence: Probiotics for maintaining remission have not consistently shown benefit in CD. Postoperative recurrence prevention with single-strain probiotics has generally been disappointing. The overall quality of evidence is limited by small sample sizes and methodological heterogeneity.

Bottom line: Probiotics are not a replacement for medical therapy in Crohn's disease. They may have a supporting role as part of a comprehensive approach that includes appropriate medical care, dietary support, and microbiome-supportive strategies — but should always be discussed with a gastroenterologist.

Why Prebiotics and Synbiotics Matter

If there is one consistent thread running through positive probiotic trials in Crohn's disease, it's that synbiotic combinations — probiotics plus prebiotic fibers — tend to outperform probiotics alone. This pattern has biological logic behind it. Probiotic bacteria need substrate to colonize, persist, and produce beneficial metabolites. Prebiotic fibers are non-digestible substrates that selectively feed beneficial bacteria, supporting their growth and metabolic activity.

The Steed trial used a combination of B. longum with prebiotic Synergy 1 (oligofructose-enriched inulin), and produced significant improvements in CDAI, histological scores, and TNF-α expression in active CD patients.^[4] The Fujimori synbiotic trial used a high-dose probiotic mix with psyllium and showed clinical improvement in 7 of 10 active CD patients.^[25]

Prebiotic Considerations in Crohn's Disease

One important caveat for CD patients: not all prebiotic fibers are equally well-tolerated, particularly during active flares or in patients with strictures. Some highly fermentable fibers can transiently increase gas production. Lower-FODMAP, gentler prebiotic fibers — such as those derived from acacia — tend to be better tolerated by sensitive guts. Our article on acacia fiber for sensitive guts covers this in more detail.

Inulin from Jerusalem artichoke, one of nature's richest sources, has been studied for its bifidogenic properties — its ability to selectively promote the growth of beneficial Bifidobacterium species. Combined with the right probiotic strains and tolerated at appropriate doses, this kind of prebiotic support is what differentiates a comprehensive synbiotic formula from a basic probiotic supplement.

The Synbiotic Approach Built Into MicroBiome Restore

MicroBiome Restore is built around the synbiotic principle. Its 26 probiotic strains are paired with 9 organic prebiotic ingredients — Jerusalem artichoke, acacia fiber, maitake mushroom, fig fruit, and several mineral-rich sea vegetables (bladderwrack, Norwegian kelp, oarweed). This combination is designed to provide both the beneficial bacteria and the fibers that support their colonization and metabolic activity in the gut.

What to Look for in a Probiotic for Crohn's Disease

Choosing a probiotic when you have Crohn's disease requires more careful attention than picking one off a drugstore shelf. The wrong formulation can be unhelpful at best — and potentially aggravating at worst. Here's what the research suggests matters most.

Vertical decision flowchart showing the five key criteria for choosing a quality probiotic for Crohn's disease support: multi-strain diversity, adequate CFU count, included prebiotics, filler-free formulation, and quality capsule materials.

Multi-Strain Diversity

The dysbiosis pattern in Crohn's disease involves multiple bacterial deficits and excesses simultaneously. Single-strain probiotics address only one piece of that puzzle. Research has shown that multi-strain probiotic preparations can regulate intestinal flora more effectively than single strains, generally restoring diversity and balance more comprehensively while producing additive or synergistic effects through multiple mechanisms.^[28] A formulation that includes both Lactobacillus and Bifidobacterium species — the two genera most consistently studied in IBD — provides broader coverage than either alone.

Clean Formulation Without Inflammatory Fillers

This is especially critical for anyone with inflammatory bowel disease. Many commercial probiotics contain inactive ingredients that have raised gut health concerns — microcrystalline cellulose, titanium dioxide (banned as a food additive in the European Union), and magnesium stearate. For someone whose intestinal lining is already inflamed, ingredient quality is not a minor consideration. Learning to spot hidden fillers on supplement labels is a skill worth developing — our guide on how to read probiotic labels walks through the specifics.

Adequate Strain Count and CFU

The clinical trials showing the most positive results in CD have generally used substantial doses — Fujimori's high-dose synbiotic delivered 75 billion CFU daily, Steed's protocol used 200 billion CFU of B. longum. While not every probiotic needs to reach those levels, products delivering only 1–5 billion CFU of a single strain are unlikely to recreate the conditions that have produced clinical benefit in the literature. A multi-strain product delivering 15 billion CFU spread across diverse, complementary species provides meaningful therapeutic-range coverage.

Prebiotic Support Built In

Given the consistent pattern of stronger results from synbiotic combinations in CD, choosing a probiotic that includes prebiotic ingredients makes sense. Look for prebiotics that are well-tolerated by sensitive guts (acacia is a good example) alongside more bifidogenic options like inulin from Jerusalem artichoke.

Capsule Quality

The capsule itself matters. Pullulan capsules, made through fermentation, are themselves a mild prebiotic and provide a delayed-release mechanism that helps protect probiotic bacteria from stomach acid — without the synthetic coatings used in some enteric capsules.

Probiotic Selection Checklist for Crohn's Disease

Look for: Multi-strain formula with both Lactobacillus and Bifidobacterium species; substantial CFU count (10–15 billion+); included prebiotic fibers tolerated by sensitive guts; clean, filler-free formulation; pullulan or other clean capsule materials; transparent strain labeling with individual species listed.

Avoid: Products with microcrystalline cellulose, titanium dioxide, magnesium stearate, or other synthetic flow agents; proprietary blends that hide individual strain amounts; single-strain formulations marketed as comprehensive solutions; products without clear strain identification.

Safety Considerations and Working With Your Doctor

Probiotics are not pharmaceuticals, but in the context of Crohn's disease, they should be approached thoughtfully — not casually. While the research consistently shows that probiotics are generally safe in CD patients, with no significant increase in serious adverse events compared to placebo across pooled trials,^[2] a few specific considerations apply to inflammatory bowel disease.

Important Safety Considerations

Probiotics do not replace medical therapy. Crohn's disease is a serious chronic condition that requires ongoing medical management. Probiotics should be considered as a potential complement to — not a substitute for — your prescribed treatment regimen.

Talk to your gastroenterologist before starting. This is especially important if you are immunocompromised, have a central venous catheter, are recovering from recent surgery, or are taking immunomodulators or biologic therapies.

Start low and go slow. Some patients experience transient gas, bloating, or changes in stool consistency when first starting a probiotic. These usually resolve within a few days. If symptoms are significant or persist, stop and consult your provider.

Be cautious during active flares. The optimal timing for introducing probiotics — during remission, during a flare, or both — is not fully established. Many gastroenterologists prefer to introduce probiotics during stable periods rather than in the middle of an acute flare.

What Probiotics Are Not

Probiotics are not anti-inflammatory drugs. They are not biologics. They are not a replacement for mesalamine, immunomodulators, steroids, or anti-TNF therapy when those are clinically indicated. Anyone considering probiotics for CD should view them as part of a broader gut-supportive strategy that complements medical care — not a path to discontinuing it.

That said, the broader literature supports a thoughtful role for probiotics in helping address the dysbiosis that consistently accompanies CD, supporting intestinal barrier function, and contributing to general digestive comfort. For patients exploring complementary approaches with their physicians, evidence-based probiotic supplementation can be one piece of that conversation.

Frequently Asked Questions

Can probiotics cure Crohn's disease?

No. Crohn's disease is a chronic immune-mediated condition with no cure currently available. Probiotics may help support gut microbiome balance and reduce certain inflammatory signals, and clinical trials suggest they may help induce clinical remission in active CD when used appropriately.^[2] But they are not a cure, and they should not replace medical therapy prescribed by a gastroenterologist.

What is the best probiotic for Crohn's disease?

There is no single "best" probiotic for Crohn's disease — the strongest research has come from multi-strain formulations and synbiotic combinations rather than any single strain. The species with the most relevant CD research include Lactobacillus casei, Bifidobacterium longum, B. breve, B. infantis, L. plantarum, and L. acidophilus, particularly when combined with prebiotic fibers. Multi-strain products that include both Lactobacillus and Bifidobacterium species, paired with well-tolerated prebiotics, reflect the formulation pattern that has produced the most consistent results in clinical research.

Are probiotics safe to take with biologics or immunosuppressants?

Across pooled clinical trial data, probiotics have demonstrated a strong safety profile in Crohn's disease patients with no significant increase in serious adverse events compared to placebo.^[2] However, patients on biologics, immunomodulators, or other immunosuppressive therapy — or those with central venous catheters or compromised immune systems — should always consult their gastroenterologist before starting any probiotic. Individual circumstances matter.

How long should I trial a probiotic before knowing if it helps?

Most positive clinical trials of probiotics in Crohn's disease have used treatment durations of 3–6 months or longer. The Steed trial showed significant improvements at 3 months that were maintained through 6 months,^[4] and the Fujimori synbiotic trial averaged 13 months of treatment.^[25] Probiotic effects are not immediate. A reasonable trial period is at least 8–12 weeks of consistent use, in coordination with your gastroenterologist, before evaluating whether the addition has been helpful.

What side effects might occur when starting a probiotic?

The most commonly reported side effects when starting a probiotic are mild and transient: temporary gas, bloating, or minor changes in stool consistency, typically resolving within a few days as the gut adjusts. The clinical literature has not identified significant safety concerns for probiotic use in CD.^[2] If symptoms are severe, persistent, or include signs of infection, stop the probiotic and consult your provider.

Why might multi-strain probiotics work better than single strains in Crohn's?

The dysbiosis pattern in Crohn's disease involves reductions in multiple beneficial bacterial groups simultaneously, alongside expansion of pro-inflammatory species. Multi-strain formulations address this through complementary mechanisms — different strains contribute different anti-inflammatory effects, barrier support, and metabolic functions. Research has shown that multi-strain preparations can regulate gut flora more comprehensively than single strains, restoring diversity through superposition or synergistic effects.^[28]

Should I avoid probiotics during a Crohn's flare?

The optimal timing for probiotic introduction in CD — during remission, flares, or both — is not definitively established by current research, and practices vary among gastroenterologists. Many providers prefer to introduce probiotics during stable periods rather than in the middle of an acute flare. This is a question to discuss directly with your treating gastroenterologist, who knows your disease pattern and current treatment.

A Thoughtful Role for Probiotics in Crohn's Disease

The science of probiotics in Crohn's disease is genuinely promising in some areas and genuinely uncertain in others. The mechanism research is compelling — specific strains can reduce pro-inflammatory cytokines in CD mucosa, strengthen the intestinal barrier, and help counter the dysbiosis that accompanies the disease. The clinical evidence supports a potential role for probiotics in inducing remission in active CD, particularly when used as a multi-strain synbiotic. But the evidence for maintaining remission and preventing postoperative recurrence remains less consistent.

What's clearer is what good probiotic selection looks like for someone with CD: a multi-strain formula spanning both Lactobacillus and Bifidobacterium genera, paired with well-tolerated prebiotic fibers, delivered in a clean formulation without the synthetic fillers that can themselves contribute to gut irritation. Equally clear is that probiotics belong as part of a comprehensive approach to Crohn's disease — alongside, not instead of, the medical therapies your gastroenterologist prescribes.

For a deeper look at how the broader microbiome supports IBD management, see our companion guide on probiotics for IBD. To understand how the MicroBiome Restore formula was built around the multi-strain, prebiotic-paired, filler-free principles supported by this research, see our complete guide to MicroBiome Restore.

A Filler-Free Synbiotic Built on Research-Backed Principles

MicroBiome Restore delivers 26 clinically studied probiotic strains, 9 organic prebiotics, and 80+ trace minerals in a single daily serving. No microcrystalline cellulose. No titanium dioxide. No magnesium stearate. Just comprehensive, multi-strain probiotic support paired with the prebiotic fibers that help beneficial bacteria thrive.

Discover MicroBiome Restore →

References

Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J. J., ... & Langella, P. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences, 105(43), 16731–16736. https://doi.org/10.1073/pnas.0804812105
Zhang, X., et al. (2025). Efficacy and safety of probiotics as adjuvant treatment for Crohn's disease: a meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2025.04.013
Llopis, M., Antolin, M., Carol, M., Borruel, N., Casellas, F., Martinez, C., Espín-Basany, E., Guarner, F., & Malagelada, J. R. (2009). Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflammatory Bowel Diseases, 15(2), 275–283. https://doi.org/10.1002/ibd.20736
Steed, H., Macfarlane, G. T., Blackett, K. L., Bahrami, B., Reynolds, N., Walsh, S. V., Cummings, J. H., & Macfarlane, S. (2010). Clinical trial: the microbiological and immunological effects of synbiotic consumption — a randomized double-blind placebo-controlled study in active Crohn's disease. Alimentary Pharmacology & Therapeutics, 32(7), 872–883. https://doi.org/10.1111/j.1365-2036.2010.04417.x
Pavel, F. M., Vesa, C. M., Gheorghe, G., Diaconu, C. C., Bungau, A. F., Rus, M., Vesa, A. F., & Bungau, S. G. (2021). Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. Diagnostics, 11(6), 1090. https://doi.org/10.3390/diagnostics11061090
Fujimoto, T., Imaeda, H., Takahashi, K., Kasumi, E., Bamba, S., Fujiyama, Y., & Andoh, A. (2013). Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. Journal of Gastroenterology and Hepatology, 28(4), 613–619. https://doi.org/10.1111/jgh.12073
Khanna, S., & Raffals, L. E. (2017). The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. Gastroenterology Clinics of North America, 46(3), 481–492. https://doi.org/10.1016/j.gtc.2017.05.004
Borruel, N., Carol, M., Casellas, F., Antolin, M., De Lara, F., Espin, E., Naval, J., Guarner, F., & Malagelada, J. R. (2002). Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut, 51(5), 659–664. https://doi.org/10.1136/gut.51.5.659
Yao, S., Zhao, Z., Wang, W., & Liu, X. (2021). Bifidobacterium Longum: Protection against Inflammatory Bowel Disease. Journal of Immunology Research, 2021, 8030297. https://doi.org/10.1155/2021/8030297
Kong, S., Zhang, Y. H., & Zhang, W. (2018). Regulation of Intestinal Epithelial Cells Properties and Functions by Amino Acids. BioMed Research International, 2018, 2819154. Plus: Hsieh, C. Y., Osaka, T., Moriyama, E., Date, Y., Kikuchi, J., & Tsuneda, S. (2024). Role of Bifidobacterium in Modulating the Intestinal Epithelial Tight Junction Barrier: Current Knowledge and Perspectives. Current Developments in Nutrition. https://doi.org/10.1016/j.cdnut.2023.102099
Le, B., & Yang, S. H. (2018). Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease. Toxicology Reports, 5, 314–317. https://doi.org/10.1016/j.toxrep.2018.02.007
Leccese, G., Bibi, A., Mazza, S., Facciotti, F., Caprioli, F., Landini, P., & Paroni, M. (2020). Probiotic Lactobacillus and Bifidobacterium Strains Counteract Adherent-Invasive Escherichia coli (AIEC) Virulence and Hamper IL-23/Th17 Axis in Ulcerative Colitis, but Not in Crohn's Disease. Cells, 9(8), 1824. https://doi.org/10.3390/cells9081824
Liu, Y., Tran, D. Q., & Rhoads, J. M. (2018). Probiotics in Disease Prevention and Treatment. The Journal of Clinical Pharmacology, 58(S10), S164–S179. https://doi.org/10.1002/jcph.1121
Javed, N. H., Alsahly, M. B., & Khubchandani, J. (2016). Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis. Scientifica, 2016, 9572596. Plus: Li, Z., et al. (2024). Both viable Bifidobacterium longum subsp. infantis and heat-killed cells alleviate the intestinal inflammation of DSS-induced IBD rats. Microbiology Spectrum, 12(6), e0350923. https://doi.org/10.1128/spectrum.03509-23
Kanamori, Y., Sugiyama, M., Hashizume, K., Yuki, N., Morotomi, M., & Tanaka, R. (2004). Experience of long-term synbiotic therapy in seven short bowel patients with refractory enterocolitis. Journal of Pediatric Surgery, 39(11), 1686–1692. https://doi.org/10.1016/j.jpedsurg.2004.07.013
Jakubczyk, D., Leszczyńska, K., & Górska, S. (2020). The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD) — A Critical Review. Nutrients, 12(7), 1973. https://doi.org/10.3390/nu12071973
Gupta, P., Andrew, H., Kirschner, B. S., & Guandalini, S. (2000). Is Lactobacillus GG Helpful in Children With Crohn's Disease? Results of a Preliminary, Open-Label Study. Journal of Pediatric Gastroenterology and Nutrition, 31(4), 453–457. https://doi.org/10.1097/00005176-200010000-00024
Bousvaros, A., Guandalini, S., Baldassano, R. N., Botelho, C., Evans, J., Ferry, G. D., ... & Hibberd, P. L. (2005). A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflammatory Bowel Diseases, 11(9), 833–839. https://doi.org/10.1097/01.mib.0000175905.00212.2c
Bergmann, K. R., Liu, S. X., Tian, R., Kushnir, A., Turner, J. R., Li, H. L., Chou, P. M., Weber, C. R., & De Plaen, I. G. (2013). Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. The American Journal of Pathology, 182(5), 1595–1606. https://doi.org/10.1016/j.ajpath.2013.01.013
Carol, M., Borruel, N., Antolin, M., Llopis, M., Casellas, F., Guarner, F., & Malagelada, J. R. (2006). Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. Journal of Leukocyte Biology, 79(5), 917–922. https://doi.org/10.1189/jlb.0405188
Vakadaris, G., Stefanis, C., Giorgi, E., Brouvalis, M., Voidarou, C. C., Kourkoutas, Y., Tsigalou, C., & Bezirtzoglou, E. (2023). The Role of Probiotics in Inducing and Maintaining Remission in Crohn's Disease and Ulcerative Colitis: A Systematic Review of the Literature. Biomedicines, 11(2), 494. https://doi.org/10.3390/biomedicines11020494
Alemu, B. K., Azeze, G. G., Wu, L., Lau, S., Wang, C., & Wang, Y. (2023). Effects of maternal probiotic supplementation on breast milk microbiome and infant gut microbiome and health: A systematic review and meta-analysis of randomized controlled trials. American Journal of Obstetrics & Gynecology MFM, 5(11), 101148. https://doi.org/10.1016/j.ajogmf.2023.101148
Bamola, V. D., Dubey, D., Samanta, P., Kedia, S., Ahuja, V., Madempudi, R. S., Neelamraju, J., & Chaudhry, R. (2022). Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease. Anaerobe, 78, 102652. https://doi.org/10.1016/j.anaerobe.2022.102652
Shinde, T., Vemuri, R., Shastri, M. D., Perera, A. P., Tristram, S., Stanley, R., & Eri, R. (2019). Probiotic Bacillus coagulans MTCC 5856 spores exhibit excellent in-vitro functional efficacy in simulated gastric survival, mucosal adhesion and immunomodulation. Journal of Functional Foods, 52, 100–108. https://doi.org/10.1016/j.jff.2018.10.031
Fujimori, S., Tatsuguchi, A., Gudis, K., Kishida, T., Mitsui, K., Ehara, A., Kobayashi, T., Sekita, Y., Seo, T., & Sakamoto, C. (2007). High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. Journal of Gastroenterology and Hepatology, 22(8), 1199–1204. https://doi.org/10.1111/j.1440-1746.2006.04535.x
Megapanou, E., Kostakou, E., Mantzouranis, M., Lazaridis, M., Christodoulou, D. K., & Tsianos, E. V. (2025). The Role of Probiotics in the Maintenance of Remission in Adult-Onset Crohn's Disease: A Systematic Review. Advanced Gut & Microbiome Research, 2025, 7773978. https://doi.org/10.1155/agm3/7773978
Limketkai, B. N., Akobeng, A. K., Gordon, M., & Adepoju, A. A. (2020). Probiotics for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, 7(7), CD006634. https://doi.org/10.1002/14651858.CD006634.pub3
Chapman, C. M., Gibson, G. R., & Rowland, I. (2011). Health benefits of probiotics: are mixtures more effective than single strains? European Journal of Nutrition, 50(1), 1–17. https://doi.org/10.1007/s00394-010-0166-z

Nicholas Wunder

Learn More

Nicholas Wunder is the founder of BioPhysics Essentials. With a degree in Biology and a background in neuroscience and microbiology, he created Gut Check to cut through supplement industry marketing noise and share what the research actually says about gut health.